Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)
Document Type
Abstract
Publication Date
3-2018
Journal Title
Biology of Blood and Marrow Transplantation
Department
Pediatrics
Second Department
Health Behavior and Community Health
Disciplines
Medicine and Health Sciences
Recommended Citation
Chu, Y., Su, N., Alter, S., Jeng, E. K., Rhode, P. R., Barth, M., Lee, D., Wong, H. C., & Cairo, M. S. (2018). Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL). Biology of Blood and Marrow Transplantation, 24 (3 Suppl.1), S75-S76. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/218
COinS
